Treatment of oligometastatic breast cancer: The role of patient selection
Up to 90 % of death from solid tumors are caused by metastases. By 2040, breast cancer (BC) is predicted to increase to over 3 million new cases. Additionally, with the personalization and intensification of BC follow-up, many patients will relapse with oligometastatic disease (OMD). Over the past d...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Breast |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S096097762400170X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856910563016704 |
|---|---|
| author | Riccardo Ray Colciago Maria Carmen De Santis Carlotta Giandini Maria Grazia Carnevale Serena Di Cosimo |
| author_facet | Riccardo Ray Colciago Maria Carmen De Santis Carlotta Giandini Maria Grazia Carnevale Serena Di Cosimo |
| author_sort | Riccardo Ray Colciago |
| collection | DOAJ |
| description | Up to 90 % of death from solid tumors are caused by metastases. By 2040, breast cancer (BC) is predicted to increase to over 3 million new cases. Additionally, with the personalization and intensification of BC follow-up, many patients will relapse with oligometastatic disease (OMD). Over the past decades, advances in treatment planning, image guidance, target position reproducibility, and online tracking, along with a compelling radiobiological rationale, have led to the implementation of Stereotactic Body Radiation Therapy (SBRT). This has become a valid ablative treatment option for OMD patients.However, there are still concerns about which patients benefit the most from ablative treatment. In this review, we will analyze the literature regarding SBRT for OMD in BC patients. We aim to present the current data on its effectiveness and define the optimal tailored scenarios for SBRT outcomes. |
| format | Article |
| id | doaj-art-7367d1fd8cad48539dff049b9e19a3bd |
| institution | Kabale University |
| issn | 1532-3080 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj-art-7367d1fd8cad48539dff049b9e19a3bd2025-02-12T05:30:33ZengElsevierBreast1532-30802025-02-0179103839Treatment of oligometastatic breast cancer: The role of patient selectionRiccardo Ray Colciago0Maria Carmen De Santis1Carlotta Giandini2Maria Grazia Carnevale3Serena Di Cosimo4School of Medicine and Surgery, University of Milan Bicocca, Milan, ItalyDepartment of Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Corresponding author. Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Via Venezian 1, Italy.Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, ItalyDepartment of Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, ItalyDepartment of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, ItalyUp to 90 % of death from solid tumors are caused by metastases. By 2040, breast cancer (BC) is predicted to increase to over 3 million new cases. Additionally, with the personalization and intensification of BC follow-up, many patients will relapse with oligometastatic disease (OMD). Over the past decades, advances in treatment planning, image guidance, target position reproducibility, and online tracking, along with a compelling radiobiological rationale, have led to the implementation of Stereotactic Body Radiation Therapy (SBRT). This has become a valid ablative treatment option for OMD patients.However, there are still concerns about which patients benefit the most from ablative treatment. In this review, we will analyze the literature regarding SBRT for OMD in BC patients. We aim to present the current data on its effectiveness and define the optimal tailored scenarios for SBRT outcomes.http://www.sciencedirect.com/science/article/pii/S096097762400170X |
| spellingShingle | Riccardo Ray Colciago Maria Carmen De Santis Carlotta Giandini Maria Grazia Carnevale Serena Di Cosimo Treatment of oligometastatic breast cancer: The role of patient selection Breast |
| title | Treatment of oligometastatic breast cancer: The role of patient selection |
| title_full | Treatment of oligometastatic breast cancer: The role of patient selection |
| title_fullStr | Treatment of oligometastatic breast cancer: The role of patient selection |
| title_full_unstemmed | Treatment of oligometastatic breast cancer: The role of patient selection |
| title_short | Treatment of oligometastatic breast cancer: The role of patient selection |
| title_sort | treatment of oligometastatic breast cancer the role of patient selection |
| url | http://www.sciencedirect.com/science/article/pii/S096097762400170X |
| work_keys_str_mv | AT riccardoraycolciago treatmentofoligometastaticbreastcancertheroleofpatientselection AT mariacarmendesantis treatmentofoligometastaticbreastcancertheroleofpatientselection AT carlottagiandini treatmentofoligometastaticbreastcancertheroleofpatientselection AT mariagraziacarnevale treatmentofoligometastaticbreastcancertheroleofpatientselection AT serenadicosimo treatmentofoligometastaticbreastcancertheroleofpatientselection |